Dec 29, 2025 7:57am EST Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Dec 29, 2025 7:45am EST Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Dec 16, 2025 7:00am EST Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Nov 24, 2025 7:00am EST Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Nov 17, 2025 7:00am EST Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
Nov 10, 2025 4:15pm EST Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
Nov 4, 2025 7:00am EST Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
